These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31455562)

  • 1. Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK.
    Rickard E; Ozieranski P; Mulinari S
    Health Policy; 2019 Dec; 123(12):1244-1250. PubMed ID: 31455562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts.
    Mulinari S; Ozieranski P
    BMJ Open; 2018 Oct; 8(10):e023094. PubMed ID: 30344175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs.
    Mulinari S; Vilhelmsson A; Rickard E; Ozieranski P
    PLoS One; 2020; 15(6):e0235021. PubMed ID: 32579571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015.
    Ozieranski P; Csanadi M; Rickard E; Tchilingirian J; Mulinari S
    JAMA Netw Open; 2019 Jun; 2(6):e196253. PubMed ID: 31225896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan.
    Saito H; Ozaki A; Sawano T; Shimada Y; Tanimoto T
    JAMA Netw Open; 2019 Apr; 2(4):e192834. PubMed ID: 31026027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency.
    Ozieranski P; Saito H; Rickard E; Mulinari S; Ozaki A
    Global Health; 2023 Mar; 19(1):14. PubMed ID: 36869318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey.
    Ball DE; Tisocki K; Herxheimer A
    BMC Public Health; 2006 Aug; 6():201. PubMed ID: 16887025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug company payments to General Practices in England: Cross-sectional and social network analysis.
    Saghy E; Mulinari S; Ozieranski P
    PLoS One; 2021; 16(12):e0261077. PubMed ID: 34874975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tip of the Iceberg? Country- and Company-Level Analysis of Drug Company Payments for Research and Development in Europe.
    Ozieranski P; Martinon L; Jachiet PA; Mulinari S
    Int J Health Policy Manag; 2022 Dec; 11(12):2842-2859. PubMed ID: 35297231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?
    Pashley D; Ozieranski P; Mulinari S
    Int J Health Serv; 2022 Jul; 52(3):347-362. PubMed ID: 35230175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Industry funding of patient organisations in the UK: a retrospective study of commercial determinants, funding concentration and disease prevalence.
    Gentilini A; Parvanova I
    BMJ Open; 2023 Jun; 13(6):e071138. PubMed ID: 37369404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016).
    Ozieranski P; Csanádi M; Rickard E; Mulinari S
    BMJ Open; 2020 Sep; 10(9):e037351. PubMed ID: 32950962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
    Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
    BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hidden web of policy influence: The pharmaceutical industry's engagement with UK's All-Party Parliamentary Groups.
    Rickard E; Ozieranski P
    PLoS One; 2021; 16(6):e0252551. PubMed ID: 34166396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Financial conflicts of interest between pharmaceutical companies and the authors of urology clinical practice guidelines in Japan.
    Yamamoto K; Murayama A; Ozaki A; Saito H; Sawano T; Tanimoto T
    Int Urogynecol J; 2021 Feb; 32(2):443-451. PubMed ID: 33151353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: Analysis of payment data in 2016.
    Ozaki A; Saito H; Senoo Y; Sawano T; Shimada Y; Kobashi Y; Yamamoto K; Suzuki Y; Tanimoto T
    Health Policy; 2020 Jul; 124(7):727-735. PubMed ID: 32439213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A 'patient-industry complex'? Investigating the financial dependency of UK patient organisations on drug company funding.
    Ozieranski P; Pitter JG; Rickard E; Mulinari S; Csanadi M
    Sociol Health Illn; 2022 Jan; 44(1):188-210. PubMed ID: 34874566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review.
    Ozieranski P; Martinon L; Jachiet PA; Mulinari S
    BMJ Open; 2021 Dec; 11(12):e053138. PubMed ID: 34916317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis.
    Rickard E; Carmel E; Ozieranski P
    BMJ Open; 2023 Mar; 13(3):e061591. PubMed ID: 36990486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension.
    Senoo Y; Saito H; Ozaki A; Sawano T; Shimada Y; Yamamoto K; Suzuki Y; Tanimoto T
    Medicine (Baltimore); 2021 Mar; 100(12):e24816. PubMed ID: 33761642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.